ESHRE good practice recommendations on recurrent implantation failure
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: How should recurrent implantation failure (RIF) in patients undergoing ART be defined and managed? SUMMARY ANSWER: This is the first ESHRE good practice recommendations paper providing a definition for RIF together with recommendations on how to investigate causes and contributing factors, and how to improve the chances of a pregnancy. WHAT IS KNOWN ALREADY: RIF is a challenge in the ART clinic, with a multitude of investigations and interventions offered and applied in clinical practice, often without biological rationale or with unequivocal evidence of benefit. STUDY DESIGN, SIZE, DURATION: This document was developed according to a predefined methodology for ESHRE good practice recommendations. Recommendations are supported by data from the literature, if available, and the results of a previously published survey on clinical practice in RIF and the expertise of the working group. A literature search was performed in PubMed and Cochrane focussing on ‘recurrent reproductive failure’, ‘recurrent implantation failure’, and ‘repeated implantation failure’. PARTICIPANTS/MATERIALS, SETTING, METHODS: The ESHRE Working Group on Recurrent Implantation Failure included eight members representing the ESHRE Special Interest Groups for Implantation and Early Pregnancy, Reproductive Endocrinology, and Embryology, with an independent chair and an expert in statistics. The recommendations for clinical practice were formulated based on the expert opinion of the working group, while taking into consideration the published data and results of the survey on uptake in clinical practice. The draft document was then open to ESHRE members for online peer review and was revised in light of the comments received. MAIN RESULTS AND THE ROLE OF CHANCE: The working group recommends considering RIF as a secondary phenomenon of ART, as it can only be observed in patients undergoing IVF, and that the following description of RIF be adopted: ‘RIF describes the scenario in which the transfer of embryos considered to be viable has failed to result in a positive pregnancy test sufficiently often in a specific patient to warrant consideration of further investigations and/or interventions'. It was agreed that the recommended threshold for the cumulative predicted chance of implantation to identify RIF for the purposes of initiating further investigation is 60%. When a couple have not had a successful implantation by a certain number of embryo transfers and the cumulative predicted chance of implantation associated with that number is greater than 60%, then they should be counselled on further investigation and/or treatment options. This term defines clinical RIF for which further actions should be considered. Nineteen recommendations were formulated on investigations when RIF is suspected, and 13 on interventions. Recommendations were colour-coded based on whether the investigations/interventions were recommended (green), to be considered (orange), or not recommended, i.e. not to be offered routinely (red). LIMITATIONS, REASONS FOR CAUTION: While awaiting the results of further studies and trials, the ESHRE Working Group on Recurrent Implantation Failure recommends identifying RIF based on the chance of successful implantation for the individual patient or couple and to restrict investigations and treatments to those supported by a clear rationale and data indicating their likely benefit. WIDER IMPLICATIONS OF THE FINDINGS: This article provides not only good practice advice but also highlights the investigations and interventions that need further research. This research, when well-conducted, will be key to making progress in the clinical management of RIF. STUDY FUNDING/COMPETING INTEREST(S): The meetings and technical support for this project were funded by ESHRE. N.M. declared consulting fees from ArtPRED (The Netherlands) and Freya Biosciences (Denmark); Honoraria for lectures from Gedeon Richter, Merck, Abbott, and IBSA; being co-founder of Verso Biosense. He is Co-Chief Editor of Reproductive Biomedicine Online (RBMO). D.C. declared being an Associate Editor of Human Reproduction Update, and declared honoraria for lectures from Merck, Organon, IBSA, and Fairtility; support for attending meetings from Cooper Surgical, Fujifilm Irvine Scientific. G.G. declared that he or his institution received financial or non-financial support for research, lectures, workshops, advisory roles, or travelling from Ferring, Merck, Gedeon-Richter, PregLem, Abbott, Vifor, Organon, MSD, Coopersurgical, ObsEVA, and ReprodWissen. He is an Editor of the journals Archives of Obstetrics and Gynecology and Reproductive Biomedicine Online, and Editor in Chief of Journal Gynäkologische Endokrinologie. He is involved in guideline developments and quality control on national and international level. G.L. declared he or his institution received honoraria for lectures from Merck, Ferring, Vianex/Organon, and MSD. He is an Associate Editor of Human Reproduction Update, immediate past Coordinator of Special Interest Group for Reproductive Endocrinology of ESHRE and has been involved in Guideline Development Groups of ESHRE and national fertility authorities. D.J.M. declared being an Associate Editor for Human Reproduction Open and statistical Advisor for Reproductive Biomedicine Online. B.T. declared being shareholder of Reprognostics and she or her institution received financial or non-financial support for research, clinical trials, lectures, workshops, advisory roles or travelling from support for attending meetings from Ferring, MSD, Exeltis, Merck Serono, Bayer, Teva, Theramex and Novartis, Astropharm, Ferring. The other authors had nothing to disclose. DISCLAIMER: This Good Practice Recommendations (GPR) document represents the views of ESHRE, which are the result of consensus between the relevant ESHRE stakeholders and are based on the scientific evidence available at the time of preparation. ESHRE GPRs should be used for information and educational purposes. They should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care, or be exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, or variations based on locality and facility type. Furthermore, ESHRE GPRs do not constitute or imply the endorsement, or favouring, of any of the included technologies by ESHRE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726 · cited 1×
“In recent years, the Human Microbiome Project has highlighted the importance of micro-organisms and their genomes in human health and disease (Human Microbiome Project Consortium, 2012).”
BackgroundMIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
The international glossary on infertility and fertility care, 2017
Zegers-Hochschild, F., Adamson, G. D., Dyer, S., Racowsky, C., de Mouzon, J., Sokol, R., Rienzi, L., Sunde, A., Schmidt, L., Cooke, I. D., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dex234 · Cited by 1,320
Bouet, P.-E., El Hachem, H., Monceau, E., Gariépy, G., Kadoch, I.-J., & Sylvestre, C. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.09.025 · Cited by 335
Endometrial microbiota composition is associated with reproductive outcome in infertile patients
Moreno, I., Garcia-Grau, I., Perez-Villaroya, D., Gonzalez-Monfort, M., Bahçeci, M., Barrionuevo, M. J., Taguchi, S., Puente, E., Dimattina, M., Lim, M. W., et al. (2022) · Microbiome · doi:10.1186/s40168-021-01184-w · Cited by 325
Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J. (2015) · European Thyroid Journal · doi:10.1159/000438750 · Cited by 323 · cited 1×
“4 mIU/l (subclinical hyperthyroidism) may be considered thyroid dysfunction and require further follow-up and treatment (Biondi et al., 2015; Poppe et al., 2021).”
BackgroundSeshadri, S., & Sunkara, S. K. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt056 · Cited by 303
Male factors and the likelihood of pregnancy in infertile couples. I. Study of sperm characteristics
JOUANNET, P., DUCOT, B., FENEUX, D., & SPIRA, A. (1988) · International Journal of Andrology · doi:10.1111/j.1365-2605.1988.tb01011.x · Cited by 260
Koedooder, R., Singer, M., Schoenmakers, S., Savelkoul, P. H. M., Morré, S. A., de Jonge, J. D., Poort, L., Cuypers, W. J. S. S., Beckers, N. G. M., Broekmans, F. J. M., et al. (2019) · Human Reproduction · doi:10.1093/humrep/dez065 · Cited by 257
The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomalies
Grimbizis, G. F., Di Spiezio Sardo, A., Saravelos, S. H., Gordts, S., Exacoustos, C., Van Schoubroeck, D., Bermejo, C., Amso, N. N., Nargund, G., Timmerman, D., et al. (2016) · Human Reproduction · doi:10.1093/humrep/dev264 · Cited by 232 · cited 1×
“Given the general diagnostic accuracy attributed to 3D transvaginal ultrasound, it has been proposed as an alternative noninvasive procedure for the diagnosis of uterine anomalies and a good practice approach (Grimbizis et al., 2016).”
BackgroundART in Europe, 2018: results generated from European registries by ESHRE
European IVF Monitoring Consortium (EIM), F. T. E. S. O. H. R. A. E. (., Gliozheni, O., Hambartsoumian, E., Strohmer, H., Petrovskaya, E., Tishkevich, O., de Neubourg, D., Bogaerts, K., Balic, D., Sibincic, S., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoac022 · Cited by 229
Kyono, K., Hashimoto, T., Kikuchi, S., Nagai, Y., & Sakuraba, Y. (2019) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12250 · Cited by 160 · cited 1×
“…a recent meta-analysis of six cohort studies, including a total of 1095 women, and several other studies have reported an association between dysbiotic microbiota and impaired reproductive outcomes (Moreno et al. , 2016, 2022; Koedooder et al. , 2019; Kyono et al. , 2019; Singer et al. , 2019).”
BackgroundChen, X., Mariee, N., Jiang, L., Liu, Y., Wang, C. C., Li, T. C., & Laird, S. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.09.010 · Cited by 91 · cited 3×
“…reductions of blood polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), myeloid-derived suppressor cells, Tregs, and nitrous oxide production by PMN-MDSCs, whereas the expression of f chain on CD4 þ T-cell receptor and CD8 þ T-cell receptor was upregulated (Jiang et al. , 2017).”
BackgroundTop 10 priorities for future infertility research: an international consensus development study
Duffy, J. M. N., Adamson, G. D., Benson, E., Bhattacharya, S., Bhattacharya, S., Bofill, M., Brian, K., Collura, B., Curtis, C., Evers, J. L. H., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.11.014 · Cited by 75
Lash, G. E., Bulmer, J. N., Li, T. C., Innes, B. A., Mariee, N., Patel, G., Sanderson, J., Quenby, S., & Laird, S. M. (2016) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2016.04.290 · Cited by 57
Metadata
- Authors
- ESHRE Working Group on Recurrent Implantation Failure, Cimadomo, D., de los Santos, M. J., Griesinger, G., Lainas, G., Le Clef, N., McLernon, D. J., Montjean, D., Toth, B., Vermeulen, N., & Macklon, N.
- Venue
- Human Reproduction Open
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-01
- Volume
- 2023
- Issue
- 3
- Pages
- hoad023-hoad023
- ISSN
- 2399-3529 (ISSN-L)
- OpenAlex
- W4380768002
- Cited by
- 237
- References
- 15
- FWCI
- 20.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.